Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00361283 · ClinicalTrials.gov registry record · Phase 4
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
A Phase 4 study of Inflammation, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT00361283: Completed Phase 4 study of Inflammation, sponsored by University of Florida.
NCT00361283 is a Phase 4 study of Inflammation that has completed, run by University of Florida. The registered enrollment target is 108 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00361283, a Phase 4 study of Inflammation, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to test whether atorvastatin (also known as Lipitor) has anti-inflammatory effects in people with no known heart disease or high cholesterol. We also are investigating whether or not genetic differences between people plays a role in the drug response.
Primary Outcome
We take difference week 16 minus week 0 for ENA-78 and use a one sample t comparison.
Conditions Studied
Interventions
- DRUG Atorvastatin
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
What the finished NCT00361283 record still lists
NCT00361283 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00361283 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00361283 about?
NCT00361283 is a clinical study titled "Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis". The purpose of the study is to test whether atorvastatin (also known as Lipitor) has anti-inflammatory effects in people with no known heart disease or high cholesterol. We also are investigating whether or not genetic differences between people plays a role in the drug response.
What is the current status of trial NCT00361283?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2004-06. Estimated completion is 2009-01.
What conditions does trial NCT00361283 study?
This clinical trial studies the following conditions: Inflammation.
What interventions are being tested in trial NCT00361283?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00361283?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00361283 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00361283's enrollment target sits among peer trials
108 43rd of 132 higher than 89 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Skin Barrier Function and Inflammation in Aging: The BIA Study
RECRUITING · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
-
Impact of Ascorbic Acid on Post-Cardiothoracic Surgery Inflammation
COMPLETED · Phase 4
-
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
COMPLETED · Phase 4
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia